• Wondering if Mirum Pharmaceuticals at around US$87.90 is still offering value after a strong run, or if most of the opportunity is already reflected in the price.
• The stock has been flat over the past week, recorded a 4.8% decline over the last 30 days, yet is up 12.6% year to date and 99.6% over the past year, with a very large 3 year gain of 252.3% and a 5 year gain of 340.6%.
• Recent coverage has focused on Mirum Pharmaceuticals as a fast moving biotech name. This helps frame why the share price has seen such strong multi-year returns. This context is important when you think about whether the current price still reflects the underlying fundamentals or has run ahead of them.
• Simply Wall St currently assigns Mirum Pharmaceuticals a valuation score of 5 out of 6. The next step is to look at how different valuation methods assess the stock and then consider an even more complete way to think about value, which is introduced at the end of this article.

Approach 1: Mirum Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today to estimate what the business might be worth right now.

For Mirum Pharmaceuticals, the latest twelve month Free Cash Flow (FCF) is reported at $34.84 million. Analysts provide explicit FCF estimates out to 2030, with Simply Wall St then extending the projections further as part of a 2 Stage Free Cash Flow to Equity model. Within these projections, FCF for 2030 is expected at $633.12 million, with earlier years including both a forecast FCF loss in 2026 of $21.09 million and rising positive FCF figures in later years, all expressed in $.

After discounting these future cash flows back to today, the model arrives at an estimated intrinsic value of $363.65 per share. Compared with the current share price of about $87.90, this DCF output suggests Mirum Pharmaceuticals is 75.8% undervalued on this methodology.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Mirum Pharmaceuticals is undervalued by 75.8%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Mirum Pharmaceuticals Price vs Sales

For companies where profits are not yet a reliable guide, the P/S ratio is often a useful way to think about value, because it compares what you pay for the stock with the revenue the business is already generating.

Growth expectations and risk still matter, because a higher growth outlook or lower perceived risk can justify a higher "normal" P/S multiple, while slower growth or higher uncertainty can point to a lower one.

Mirum Pharmaceuticals currently trades on a P/S ratio of 10.17x. That is very close to the Biotechs industry average P/S of 10.17x and also sits near the peer group average of 11.09x, so on simple comparisons the stock is roughly in line with its sector.

Simply Wall St also calculates a proprietary “Fair Ratio” for Mirum Pharmaceuticals of 9.68x. This is designed to reflect the P/S multiple that might be expected given factors such as the company’s earnings growth profile, profit margins, industry, market cap and key risks.

This Fair Ratio can be more useful than a basic peer or industry comparison, because it adjusts for company specific qualities rather than assuming all Biotechs deserve the same multiple.

Since the current 10.17x P/S is above the 9.68x Fair Ratio by more than 0.10, the shares screen as slightly expensive on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Mirum Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and that is through Narratives, which let you attach a clear story about Mirum Pharmaceuticals to the numbers by linking your view of future revenue, earnings and margins to a forecast and then to a fair value that can be compared with the current share price.

On Simply Wall St’s Community page, Narratives are available as an easy tool used by millions of investors. They allow you to pick or adjust a scenario, see how that flows through to a financial model, and then check whether the implied Fair Value is above or below today’s market price to help you decide if Mirum looks more interesting to you or less so at a given time.

Narratives are refreshed when new information arrives, such as company news or earnings. That is why Mirum currently has very different published views, with one community Narrative using a Fair Value of US$140.00 per share on the optimistic end and another using US$95.00 on the cautious end, while the consensus style Narrative sits in the middle at US$106.60. This gives you a clear range of perspectives to compare with the latest price.

Do you think there's more to the story for Mirum Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.